IRAK-1-4 Inhibitor I 25 mg | 100.00%
TargetMol
IRAK-1-4 Inhibitor I
Search Results
IRAK-1-4 Inhibitor I 5 mg | 100.00%
TargetMol
IRAK-1-4 Inhibitor I
INCB032304 50 mg | 100.00%
TargetMol
INCB032304 is an important pharmaceutical intermediate. It can be used in the preparation of Ruxolitinib phosphate (I008849), a janus kinase inhibitor, and in the preparation of Barretinib.
More Information Supplier PageINCB032304
INCB032304 25 mg | 100.00%
TargetMol
INCB032304 is an important pharmaceutical intermediate. It can be used in the preparation of Ruxolitinib phosphate (I008849), a janus kinase inhibitor, and in the preparation of Barretinib.
More Information Supplier PageINCB032304
KU-0063794 5 mg | 98.35%
TargetMol
KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2.
More Information Supplier PageKU-0063794 50 mg | 98.35%
TargetMol
KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2.
More Information Supplier PageKU-0063794 25 mg | 98.35%
TargetMol
KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2.
More Information Supplier PageKU-0063794 10 mg | 98.35%
TargetMol
KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2.
More Information Supplier PageBortezomib 10 mg | 98.00%
TargetMol
Bortezomib (PS-341) is a potent 20S proteasome inhibitor (Ki: 0.6 nM, in a cell-free assay).
More Information Supplier PageBortezomib
Bortezomib 100 mg | 98.00%
TargetMol
Bortezomib (PS-341) is a potent 20S proteasome inhibitor (Ki: 0.6 nM, in a cell-free assay).
More Information Supplier PageBortezomib